PLAINSBORO, N.J. and BERLIN, May 23, 2017 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, announced today that it has signed an agreement with aap Implantate AG (“aap”) to distribute the LOQTEQ® Distal Radius System within the United States. Berlin-based aap is a globally operating medical device company developing, manufacturing and marking trauma products for orthopedics.
“Integra is a leader in the hand and wrist arthroplasty market,” said Bob Davis, corporate vice president and president, Orthopedics and Tissue Technologies. “Adding a wrist plating system to our portfolio elevates Integra into a one-stop solution for our customers’ wrist needs- from fracture plating to fusion and arthroplasty.”
The LOQTEQ® distal radius system features state-of-the-art designs with multiple plate options to accommodate a variety of fracture patterns and anatomies, as well as instrumentation designed for intra-operative efficiency.
Bruke Seyoum Alemu, CEO of aap, said, “We are looking forward to expanding our footprint in the US with a proven force in the upper extremity field. The alliance between aap and Integra is a natural fit for both companies and will additionally drive our dynamic development in North America.”
Integra’s industry-leading products in the upper extremity market include the Freedom Wrist Arthroplasty System and the PyroCarbon MCP prosthesis.
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
aap’s aspiration is to make trauma treatment better and cost-effective through innovations dedicated to create a sustainable value for patients, surgeons and hospitals. The company provides a comprehensive plates and screws portfolio for mainstream trauma and has a pipeline with new innovative products. aap’s IP-protected core platform technologies are the LOQTEQ® locking compression technology, its antimicrobial silver coating technology and its resorbable coated magnesium implants technology. For more information, please visit www.aap.de.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company Investors Nora Brennan 609-936-2488 firstname.lastname@example.org Michael Beaulieu 609-750-2827 email@example.com Media Laurene Isip 609-750-7984 firstname.lastname@example.org aap Implantate AG Fabian Franke +49 (0)30 / 750 19 134 email@example.com